Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004775-78
    Sponsor's Protocol Code Number:1014802-203
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-06-01
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2015-004775-78
    A.3Full title of the trial
    A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
    Een Gerandomiseerde, Dubbelblinde, Placebogecontrolleerde, Parallelle Groepen Studie om de Effectiviteit en Veiligheid van BIIB074 te evalueren bij Patiënten met Neuropathische Pijn door Lumbosacrale Radiculopathie
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
    Studie om de effectiviteit en veiligheid van BIIB074 te evalueren bij Patiënten met Pijn door Lumbosacrale Radiculopathie.
    A.4.1Sponsor's protocol code number1014802-203
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorConvergence Pharmaceuticals Ltd
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportConvergence Pharmaceuticals Ltd
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationConvergence Pharmaceuticals Ltd
    B.5.2Functional name of contact pointN/A
    B.5.3 Address:
    B.5.3.1Street AddressMaia Building, Babraham Research Campus
    B.5.3.2Town/ cityCambridge
    B.5.3.3Post codeCB22 3AT
    B.5.3.4CountryUnited Kingdom
    B.5.6E-mailclinicaltrials@biogen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBIIB074
    D.3.2Product code BIIB074
    D.3.4Pharmaceutical form Coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRaxatrigine (proposed)
    D.3.9.1CAS number 934240-31-0
    D.3.9.2Current sponsor codeBIIB074
    D.3.9.3Other descriptive nameCNV1014802A
    D.3.9.4EV Substance CodeSUB32074
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBIIB074
    D.3.2Product code BIIB074
    D.3.4Pharmaceutical form Coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRaxatrigine (proposed)
    D.3.9.1CAS number 934240-31-0
    D.3.9.2Current sponsor codeBIIB074
    D.3.9.3Other descriptive nameCNV1014802A
    D.3.9.4EV Substance CodeSUB32074
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCoated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Neuropathic Pain From Lumbosacral Radiculopathy
    Neuropathische Pijn door Lumbosacrale Radiculopathie
    E.1.1.1Medical condition in easily understood language
    Neuropathic Pain From Lumbosacral Radiculopathy
    Neuropathische Pijn door Hernia
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level LLT
    E.1.2Classification code 10054095
    E.1.2Term Neuropathic pain
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10050219
    E.1.2Term Lumbar radiculopathy
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to evaluate the efficacy of 2 dose regimens of BIIB074 on neuropathic pain in subjects with PLSR.
    Het primaire doel van de studie is om de effectiviteit op neuropathische pijn van 2 doseringregimes van BIIB074 te evalueren bij patiënten met PLSR.
    E.2.2Secondary objectives of the trial
    A secondary objective is to evaluate the efficacy of 2 dose regimens of BIIB074 on additional neuropathic pain measures and assessments of low back pain, disability, and quality of life.
    Een secundair doel is om de effectiviteit van 2 doseringregimes van BIIB074 op additionele neuropathische pijnmetingen en diagnostiek van lage rugpijn, invaliditeit en kwaliteit van leven te evalueren bij patiënten met PLSR.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    To be eligible to participate in this study, candidates must meet the following eligibility criteria at Screening or at the timepoint specified in the individual eligibility criterion listed:

    1. Is able to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations.
    2. Is aged 18 to 75 years, inclusive, at the time of informed consent.
    3. All women of childbearing potential and all men must practice effective contraception during the study and for 5 weeks for women and 14 weeks for men, after their last dose of study treatment. For further details of contraceptive requirements for this study, please refer to Section 15.5.
    4. Has body weight ≥50 kg for men and ≥45 kg for women.
    5. Must have diagnosis of neuropathic PLSR with ALL of the following characteristics:
    a. Pain perceived in 1 or both legs at areas consistent with the area innervated by the L4, L5, or S1 nerve roots.
    b. Evidence of asymmetrical sensory symptoms (hypoesthesia, hyperesthesia, or
    allodynia) in the affected areas (typically, the pain may be perceived in the buttock, thigh, calf, foot, or toes).
    c. History of pain suggestive that the cause of PLSR is due to injury of the lumbosacral nerve root(s) by degenerative disease of the vertebrae in the lumbosacral spine or associated soft tissues including the intervertebral discs, or secondary to spinal injury and not due to infection/abscess, hematoma, or malignancy.
    d. Pain in the legs must be more severe than pain in the back and must be asymmetrical.
    6. Has computed tomography (CT) or magnetic resonance imaging (MRI) available that does not show evidence of exclusionary pathology (see exclusion criteria); if not available or has not been conducted within 12 months prior to Screening, MRI must be conducted at Screening. CT is acceptable for subjects with contra-indications for MRI (e.g. metallic implants).
    7. Has duration of neuropathic (leg) pain of at least 6 months before Screening.
    8. Has stable intensity of neuropathic (leg) pain, with fairly continual pain (but may be worse during rest or at night) for the 4 weeks prior to Screening, based on clinical history.
    9. Has an intensity of ≥4 and ≤9 on the Numerical Rating Scale based on a paper-based question at Screening and on Day 1 that asks for the average pain intensity of neuropathic (leg) pain due to PLSR over the last week
    10. If taking approved concomitant pain medications (i.e., NSAIDs), must be on a stable regimen for at least 4 weeks before Day 1.

    Inclusion Criteria: Randomization

    To be eligible to be randomized in this study, candidates must meet the following eligibility criteria at the Randomization Visit (Day 15, Week 2):

    1. Continues to meet inclusion criteria (above).
    2. Has a baseline weekly average daily pain score for neuropathic pain (leg pain) due to PLSR ≥4 and ≤9 on the electronic diary PI-NRS; baseline is defined as the 7 days prior to randomization (nominal Days 8 to 14, with randomization on Day 15).
    3. Completed washout of concomitant pain medications except NSAIDs (see Section 7).
    Om geschikt te zijn voor deze studie dienen kandidaten aan de volgende geschiktheidscriteria te voldoen bij screening of aan individuele opgesomde criteria op het gespecificeerde tijdstip:

    1. Is in staat het doel en de risico's van de studie te begrijpen en getekende en met datum voorziene geïnformeerde toestemming en authorisatie te geven om vertrouwelijke gezondheidsinformatie in overeenstemming met nationale en lokale proefpersoon privacywetten te gebruiken.
    2. Is tussen 18 tot en met 75 jaar ten tijde van het geven van toestemming.
    3. Alle vruchtbare vrouwen en alle mannen moeten effectieve voorbehoeding toepassen gedurende de studie en voor vrouwen geldt gedurende 5 weken na en mannen 14 weken na de laatste dosis studiebehandeling. Voor verdere details van voorbehoudseisen in deze studie, lees aub sectie 15.5. 4. Heeft een lichaamsgewicht ≥ 50 kg voor mannen en ≥45 kg voor vrouwen.
    5. Moet een diagnosis hebben van neuropathische PLSR met ALLE van de volgende karakteristieken: a. Pijn waargenomen in 1 of beide benen in gebieden overeenkomend met het gebied dat geïnnerveerd wordt door de L4, L5 of S1 zenuwwortels. b. Bewijs van a-symmetrische gevoelssymptomen (hypoesthesie, hyperesthesie, of allodynie) in de aangedane gebieden (gewoonlijk kan de pijn worden waargenomen in de bil, dij, kuit, voet of tenen). c. Verleden van pijn erop wijzend dat de oorzaak van pijn het gevolg is van de lumbosacrale zenuwwortel(s) door degeneratieve ziekte van de ruggewervel in het lumbosacrale ruggemerg of hiermee in verband gebrachte zachte weefsels inclusief de intervertrebale schijven of secundair aan ruggemerletsel en niet het gevolg van infectie/abces, hematoom of kwaadaardigheid. d. Pijn in de benen moet ernstiger zijn dan pijn in de rug en dient a-symmetrisch te zijn.
    6. Er is een computer tomografie (CT) of magnetische resonantie scan (MRI) aanwezig die geen bewijs van uit te sluiten pathologie laat zien (zie exclusiecriteria); indien niet aanwezig of het werd niet gedaan binnen 12 maanden voor Screening, een MRI moet gedaan worden bij Screening. CT is acceptabel voor proefpersonen met contra-indicaties voor MRI (bv. metalen imlantaten).
    7. Er is neuropathische (been)pijn voor de duur van tenminste 6 maanden voor Screening.
    8. Heeft een stabiele intensiteit van neuropathische (been)pijn, met tamelijk continue pijn (maar kan 's nachts of in rust erger zijn) gedurende de 4 weken voor Screening, gebaseerd op klinisch verleden.
    9. Heeft een intensiteit van ≥4 and ≤9 op de op de Numerical Rating Scale gebaseerd op een vraag op papier tijdens Screening en op Dag 1 die vraagt naar de gemiddelde pijnintensiteit van neuropathische (been)pijn als gevolg van PLSR tijdens de laatste week.
    10. Als tegelijkertijd goedgekeurde pijnmedicatie (b.v. NSAID's) wordt genomen, dient deze op een stabiel regime te zijn tenminste 4 weken voor Dag 1.

    Inclusiecriteria: Randomisatie

    Om geschikt te zijn om gerandomiseerd te worden in deze studie, dienen kandidaten aan de volgende geschiktheidscriteria te voldoen gedurende de Randomisatievisite (Dag 15, Week 2);

    1. Blijft aan inclusiecriteria voldoen (boven).
    2. Heeft een baseline wekelijks gemiddelde dagelijkse pijnscore voor neuropathische pijn (beenpijn) a.g.v. PLSR ≥4 en ≤9 in het electronisch dagboek PI-NRS; baseline is gedefinieerd als de 7 dagen voor randomisatie (nominale Dagen 8 tot 14, met randomisatie op Dag 15).
    3. Gedane uitwassing van gelijktijdig gegeven pijnmedicatie behalve NSAIDs (zie Sectie 7)
    E.4Principal exclusion criteria
    Key Exclusion Criteria:
    - Has pain of a different type in the legs (e.g. due to arthritis) that may interfere with the assessment of neuropathic pain in the legs.
    -Has planned surgical intervention for PLSR within the duration of the study.
    - Has a history of peripheral neuropathy (e.g., due to diabetes, alcohol consumption, other causes, or idiopathic) or evidence of peripheral neuropathy upon neurological examination
    - Has a history or risk of seizures or a history of epilepsy, clinically significant head injury, or related neurological disorders
    - Unable to discontinue prior to Day 1 any prohibited concomitant monoamine oxidase inhibitors (MAOIs), potent CYP3A4 inducers or inhibitors, potent UGT inducers or inhibitors, including over the counter preparations, herbal remedies, vitamin, mineral supplements, food or drinks as detailed in 11.5.1.2
    - Is pregnant or lactating (female subjects only).
    - Male subject whose partner is pregnant
    -Has used paracetamol/acetaminophen at a daily dose of equal to or more than 2.5g/day on 5 or more days during 7 consecutive days in the run in phase.
    - Other protocol-defined inclusion/exclusion criteria may apply.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint that relates to this objective is the change from Baseline (Week 2) to Week 14 in the weekly average of the daily neuropathic pain* score on the 11-point PI-NRS. Subjects will be asked every evening to rate their overall neuropathic pain for the last 24-hour period. *Neuropathic pain will be evaluated in the worse affected leg, as identified at Screening.
    *Neuropathic pain will be evaluated in the worse affected leg, as identified at Screening.
    De primaire onderzoeksvariabele verwijst naar de verandering van Baseline (Week 2) tot Week 14 in het wekelijks gemiddelde van de dagelijkse neuropathische pijnscore op de 11-punten PI-NRS. Proefpersonen zullen elke avond gevraagd worden hun algehele neuropathische pijn van de laatste 24 uur te beoordelen.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 14 last 24-hour period.
    Week 14 last 24-uurs periode.
    E.5.2Secondary end point(s)
    Efficacy endpoints in neuropathic pain:
    1. 50% neuropathic daily pain reduction response (yes/no) at Week 14, where a
    response is defined as a ≥50% reduction in the weekly average of the daily
    neuropathic pain score from Baseline (Week 2) to Week 14
    2. 30% neuropathic daily pain reduction response (yes/no) at Week 14, where a
    response is defined as a ≥30% reduction in the weekly average of the daily
    neuropathic pain score from Baseline (Week 2) to Week 14
    3. Changes from Baseline (Week 2) in the weekly average of the daily neuropathic
    pain score at each visit
    Efficacy endpoint in low back pain:
    4. Change from Baseline (Week 2) to Week 14 in the weekly average of the daily
    pain score for low back pain; subjects will be asked every evening to rate their
    overall low back pain for the last 24-hour period
    Other efficacy endpoints:
    5. Patient Global Impression of Change (PGIC) responder (yes/no) at Week 14,
    where a responder is defined as either “much improved” or “very much
    improved”
    6. Change from Baseline (Week 2) to Week 14 on the Oswestry Disability Index
    7. Change from Baseline (Week 2) to Week 14 in the weekly average of the daily
    sleep score; subjects will be asked every morning to rate on the 11-point Sleep
    Numerical Rating Scale (S-NRS) how leg pain interfered with their sleep quality
    8.Change from Baseline (Week 2) to Week 14 in the Brief Pain Inventory (BPI)-
    Interference index
    9. Change from Baseline (Week 2) to Week 14 in the BPI-Pain index
    10. Change from Baseline (Week 2) to Week 14 on the EuroQoL 5-Dimension
    5-Level Questionnaire (EQ-5D-5L) health index
    11. Change from Baseline (Week 2) to Week 14 in the Short Form 36 Questionnaire
    (SF-36)
    12. Amount of rescue medication used (dosage/day)
    Another secondary objective is to investigate the safety and tolerability of 2 dose regimens of BIIB074.
    The endpoints that relate to this objective are as follows:
     AEs and SAEs
     Vital signs
     ECG parameters
     Laboratory safety tests
     Columbia-Suicide Severity Rating Scale (C-SSRS)
    Another secondary objective is to characterize the PK of BIIB074 in this population.
    Onderzoeksvariabele betreffende effectiviteit: 1. 50% neuropathische dagelijkse pijn reductierespons (ja/nee) op Week 14, waarbij een respons is gedefinieerd als een ≥50% reductie in het wekelijkse gemiddelde van de dagelijkse neuropathische pijnscore van Baseline (Week 2) tot Week 14 2. 30% neuropathische dagelijkse pijn reductierespons (ja/nee) op Week 14, waarbij een respons is gedefinieerd als een ≥30% reductie in het wekelijkse gemiddelde van de dagelijkse neuropathische pijnscore van Baseline (Week 2) tot Week 14 3. Veranderingen van Baseline (Week 2) in het wekelijks gemiddelde van de dagelijkse neuropathische pijnscore bij elke visite Onderzoeksvariabele betreffende effectiviteit bij lage rugpijn: 4. Verandering van Baseline (Week 2) tot Week 14 in het wekelijkse gemiddelde van de dagelijkse pijnscore voor lage rugpijn; proefpersonen zullen elke avond gevraagd worden om hun algehele lage rugpijnvan de laatste 24 uur te scoren. Andere effectiviteit onderzoeksvariabelen: 5. Patient Global Impression of Change (PGIC) succes (ja/nee) op Week 14, waarbij succes gedefinieerd is als ofwel "veel verbeterd" of "erg veel verbeterd" 6. Verandering t.o.v. Baseline (Week 2) tot Week 14 op de Oswestry Disability Index 7. Verandering t.o.v. Baseline (Week 2) tot Week 14 in het wekelijkse gemiddelde van de dagelijkse slaapscore; proefpersonen zullen elke morgen worden gevraagd om op de 11-punten Sleep Numerical Scale (S-NRS) te scoren hoe beenpijn interfereerde met hun slaapkwaliteit 8. Verandering t.o.v. Baseline (Week 2) tot Week 14 op de Brief Pain Inventory (BPI)-Interference index 9. Verandering t.o.v. Baseline (Week 2) tot Week 14 op de BPI-Pain index 10. Verandering t.o.v. Baseline (Week 2) tot Week 14 op de EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) health index 11. Verandering t.o.v. Baseline (Week 2) tot Week 14 op de Short Form 36 Vragenlijst (SF-36) 12. De gebruikte hoeveelheid noodmedicatie (dosering/dag) Een andere secundair doel is om de veiligheid en tolerantie van 2 dosis regimes te onderzoeken van BIIB074. De onderzoeksvariabelen die aan dit doel raken zijn als volgt: AEs en SAEs Vitale functies ECG parameters Laboratorim veiligheids tests Columbia-Suicide Severity Rating Scale (C-SSRS) Een andere secundair doel is om de PK van BIIB074 bij deze populatie te karakteriseren.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Points 1; 2; 6 - Week 14
    Point 3 - Changes from Baseline (Week 2) in the weekly average of the daily neuropathic pain score at each visit.
    Point 4-11 -Change from Baseline (Week 2) to Week 14
    Punten 1-2; 4-12 - Week 14 .
    Punt 3 - Veranderingen t.o.v. Baseline (Week 2) in het wekelijks gemiddelde van de dagelijkse neuropathische pijnscore bij elke visite.
    Punten 4-11 - Verandering t.o.v. Baseline (Week 2) tot Week 14.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Verdraagbaarheid
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA60
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Bulgaria
    Czech Republic
    France
    Georgia
    Italy
    Latvia
    Netherlands
    Romania
    Serbia
    Slovakia
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLP
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days3
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 400
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 104
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state28
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 434
    F.4.2.2In the whole clinical trial 504
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Eligible subjects may continue into the extension study, Study 1014802-204.
    Geschikte proefpersonen mogen verdergaan in de vervolgstudie, studie 1014802.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-06-01
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-02-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-08-06
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA